🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,046 results for “infusion” Clear

  1. donor-derived NK cell infusion

    Chongqing Precision Biotech Co., Ltd

    Non-small Cell Lung Cancer

    phase 2 mab active

    1 trial

  2. evorpacept, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Wuhan Createrna Science and Technology Co., Ltd

    metastatic or unresectable, recurrent HNSCC

    phase 2 small molecule active

    1 trial

  3. favezelimab, quavonlimab, Lenvatinib, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Lenvatinib

    Merck Sharp and Dohme

    Stage IV non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  4. iCasp9M28z T cell infusions

    United Therapeutics Europe Ltd

    Malignant Pleural Disease

    phase 2 gene therapy active

    1 trial

  5. infusion of MYOCET

    Teva Pharma GmbH

    Cerebral Lymphoma B Cell Refractory

    phase 2 small molecule terminated

    1 trial

  6. intravenous infusion (IV) of Adebrelimab (ADE)

    The First People's Hospital of Lianyungang

    Advanced Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  7. linrodostat mesylate; IDO1 inhibitor, linrodostat mesylate; IDO1 inhibitor, Ipilimumab, Relatlimab intravenous, OPDIVO 10 mg/mL concentrate for solution for infusion., linrodostat mesylate; IDO1 inhibitor, Ipilimumab

    Bristol-Myers Squibb Australia Pty Ltd

    Advanced Malignant Tumors

    phase 2 small molecule active

    1 trial

  8. lurbinectedin, JEMPERLI 500 mg concentrate for solution for infusion

    The George Institute

    Advanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based Chemotherapy

    phase 2 small molecule active

    1 trial

  9. pelareorep, Tecentriq 840 mg concentrate for solution for infusion

    ONCOLYTICS BIOTECH INC

    Patients with advanced or metastatic gastrointestinal (GI) tumors.

    phase 2 small molecule active

    1 trial

  10. rolistobart, KEYTRUDA 25 mg/mL concentrate for solution for infusion, PACLITAXEL , CARBOPLATIN , MK-4830, MK-4830, PEMETREXED , boserolimab, vibostolimab

    Merck Sharp and Dohme

    non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  11. rolistobart, MK-4830, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4830

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  12. rolistobart, boserolimab, MK-4830, KEYTRUDA 25 mg/mL concentrate for solution for infusion, MK-4830

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. sodium chloride 9 mg/ml (0.9%) solution for injection, LIBTAYO 350 mg concentrate for solution for infusion.

    The George Institute

    Merkel Cell Carcinoma

    phase 2 small molecule active

    1 trial

  14. ssCART-19 cells combined with CD19+ feeding T cells (FTCs) infusion

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia, Adult B-Cell

    phase 2 mab active

    1 trial

  15. teclistamab, Privigen 100 mg/ml solution for infusion, Privigen 100 mg/ml solution for infusion, teclistamab, Privigen 100 mg/ml solution for infusion

    Janssen-Cilag International N.V.

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  16. 15O-WATER, Natriumklorid Fresenius Kabi, 9 mg/ml, infusionsvätska, lösning, AZD3427, Dopamin Fresenius 50 mg/5 ml, Konzentrat zur Herstellung einer Infusionslösung, Placebo for AZD3427 or AZD3427 diluent

    AstraZeneca AB

    Heart failure with reduced ejection fraction, Renal impairment

    phase 1 small molecule active

    1 trial

  17. A Clinical Study to Assess the Safety, Tolerability of JNJ-63733657 and to evaluate how fast and to what extent JNJ-63733657 reaches the bloodstream and is absorbed, modified and removed from the body when administered as a Subcutaneous Infusion Using a Syringe Pump and as an Intravenous Infusion in Healthy Adult Participants

    Janssen-Cilag International N.V.

    Alzheimer's Disease (Healthy Participants)

    phase 1 other active

    1 trial

  18. A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants with Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)

    AbbVie Deutschland GmbH & Co. KG

    Systemic Lupus Erythematosus, Sjogren's disease

    phase 1 other active

    1 trial

  19. A Study to Learn How a Tablet Compared with an IV Infusion of the Study Medicine Called Vepdegestrant is Taken up into the Blood in Healthy Adults.

    Pfizer Australia Pty Ltd

    ER+/HER2- breast cancer

    phase 1 other active

    1 trial

  20. A randomized, single-blind, placebo-controlled, study to examine the safety, tolerability, and pharmacokinetics of M6229 administered as a 120-hour continuous infusion at two dose levels versus placebo in healthy subjects

    Lacuna Pharma Pty Ltd

    Sepsis and Septic Shock

    phase 1 other active

    1 trial

  21. A study to investigate the safety and pharmacological effect of a single intravenous infusion of GSK2857914 in male and female participants aged 18 to 75 with moderate to severe systemic lupus erythematosus

    GlaxoSmithKline

    Systemic Lupus Erythematosus

    phase 1 other active

    1 trial

  22. Allo-depleted lymphocyte infusion

    Lxo Ireland Designated Activity Company

    Transplant-Related Hematologic Malignancy

    phase 1 other terminated

    1 trial

  23. Anti-CDH17 CAR-T cells infusion

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    CDH17-positive Advanced Solid Tumors

    phase 1 mab active

    1 trial

  24. Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion, Neupogen 30 MU (0,6 mg/ml) solución inyectable en jeringa precargada filgrastim, Mozobil 20 mg/ml solution for injection, Merilen

    Lacuna Pharma Pty Ltd

    Inherited metabolic disorder of the enzyme pyruvate kinase which affects the survival of red blood cells, Pyruvate Kinase Deficiency

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources